649 656
[6]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507: 315–22.
[7]
Kim J, Akbani R, Creighton CJ, et al. Invasive bladder cancer: geno- mic insights and therapeutic promise. Clin Cancer Res 2015;21: 4514–24.
[8]
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.[9]
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152–65.
[10]
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.
[11]
Sfakianos JP, Cha EK, Iyer G, et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol 2015;68:970–7.[12]
Wang L, Ni X, Covington KR, et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differ- entiation genes. Nat Genet 2015;47:1426–34.[13]
Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequenc- ing. Genome Res 2012;22:568–76.
[14]
Shinbrot E, Henninger EE, Weinhold N, et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mu- tation patterns and human origins of replication. Genome Res 2014;24:1740–50.
[15]
Gingras MC, Covington KR, Chang DK, et al. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep 2016;14:907–19.[16] Covington K, Shinbrot E, Wheeler DA. Mutation signatures reveal
biological processes in human cancer. bioRxiv.
http://doi.org/10. 1101/036541.
[17]
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of muta- tional processes in human cancer. Nature 2013;500:415–21.
[18]
McPherson A, Hormozdiari F, Zayed A, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011;7:e1001138.[19]
Maher CA, Palanisamy N, Brenner JC, et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009;106:12353–8.[20]
Hennessy BT, Lu Y, Gonzalez-Angulo AM, et al. A technical assess- ment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast can- cers. Clin Proteomics 2010;6:129–51.[21] Fernandez MMI, Shariat SF, Margulis V, et al. Evidence-based sex-
related outcomes after radical nephroureterectomy for upper tract
urothelial carcinoma: results of large multicenter study. Urology
2009;73:142–6
. http://dx.doi.org/10.1016/j.urology.2008.07.042.
[22]
Funauchi Y, Tanikawa C, Yi Lo PH, et al. Regulation of iron homeo- stasis by the p53-ISCU pathway. Sci Rep 2015;5:16497.[23]
Stein S, Thomas EK, Herzog B, et al. NDRG1 is necessary for p53- dependent apoptosis. J Biol Chem 2004;279:48930–40.[24]
Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61.[25]
Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795–803.
[26]
Cascio S, Finn OJ. Complex of MUC1, CIN85 and Cbl in colon cancer progression and metastasis. Cancers (Basel) 2015;7:342–52.[27]
Samoylenko A, Vynnytska-Myronovska B, Byts N, et al. Increased levels of the HER1 adaptor protein Rukl/CIN85 contribute to breast cancer malignancy. Carcinogenesis 2012;33:1976–84.
[28]
Wakasaki T, Masuda M, Niiro H, et al. A critical role of c-Cbl- interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway. Neoplasia 2010;12:789–96.[29]
Dikic I. CIN85/CMS family of adaptor molecules. FEBS Lett 2002;529: 110–5.
[30]
Yakymovych I, Yakymovych M, Zang G, et al. CIN85 modulates TGFbeta signaling by promoting the presentation of TGFbeta recep- tors on the cell surface. J Cell Biol 2015;210:319–32.
[31]
Soria JC, Italiano A, Cervantes A, et al. Safety and activity of the pan– fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma. Ann Oncol 2016;27(Suppl 6):781PD.[32]
Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805–11.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 4 1 – 6 4 9
649